NCT06752096 Robot-Assisted Neurovascular Intervention
| NCT ID | NCT06752096 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Navigantis Inc. |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-12-27 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2024-12-27 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients scheduled for neurovascular interventions may be eligible to have their procedure done robotically.
Eligibility Criteria
Inclusion Criteria: Patients scheduled for neurovascular interventions, such as diagnostic cerebral angiography for cerebrovascular diseases, arterial embolization for meningioma treatment, and thrombectomy for thrombotic arterial occlusion-induced cerebral ischemia, are selected according to the same criteria as standard cerebral angiography and interventional procedures. Exclusion Criteria: Exclusion Criteria 1 (General): 1. Patients who have undergone surgery within 4 weeks prior to study participation or have not fully recovered from surgery. 2. Patients who are pregnant or breastfeeding. 3. Patients with existing or anticipated vasospasm, bleeding, or severe atheromatous disease. 4. Patients allergic to contrast agents used in angiography. 5. Patients with renal failure. 6. Patients with a history of cardiac events, such as myocardial infarction or superior vena cava (SVC) syndrome, within 3 months prior to study participation, or with existing heart disease. 7. Patients unable to cooperate due to difficulty in expressing intent to the extent that the procedure cannot proceed. 8. Patients with severe or life-threatening comorbidities that could significantly affect symptom improvement or render the procedure unbeneficial. 9. Patients with non-life-threatening comorbidities that prevent proper follow-up for treatment. Exclusion Criteria 2 (Cerebral Ischemic Stroke Patient): 1. Patients with an ASPECTS score of 0-2 on a pre-treatment non-contrast CT. 2. Inability to perform femoral puncture within 60 minutes of completing CT angiography (if CT perfusion is performed, it must be done after CT angiography). 3. Absence of a femoral pulse. 4. Cases where vascular access is highly challenging, with an anticipated time exceeding 90 minutes from CT angiography to reperfusion. 5. Patients suspected to have cerebral artery dissection or atherosclerosis as the cause of stroke. 6. Patients where the intracranial occlusion is determined to be chronic based on clinical history, prior imaging, or clinical judgment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06752096 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06752096 currently recruiting?
Yes, NCT06752096 is actively recruiting participants. Contact the research team at kenlock@navigantis.co for enrollment information.
Where is the NCT06752096 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06752096 clinical trial?
NCT06752096 is sponsored by Navigantis Inc.. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.